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Abstract: 
Extended-release medications are widely prescribed across the spectrum of medical specialties; 
however, there is heterogeneity in how they are formulated. Commonly, they consist of an 
insoluble matrix or shell from which drug elutes, which may then be observed by patients when 
excreted in feces. In this report, we describe a patient who ingested a large amount of 
extended-release bupropion tablets and subsequently passed a large number of these so-called 
"ghost tablets." 
Main Text (447 words): 
A 19-year-old male presented to our hospital in status epilepticus following an intentional 
overdose of an unknown substance. He had access to bupropion XL, vortioxetine, lithium 
carbonate, and lurasidone. He had prolonged QRS and QTc on EKG, hypotension requiring 
vasopressors, and tachycardia, symptoms which are consistent with bupropion toxicity. To 
support the clinical diagnosis, serum bupropion and hydroxybupropion levels were performed 
on blood taken on admission; these later returned positive at 1800ng/mL (therapeutic 
~100ng/mL) and 4200ng/mL, respectively. A lithium serum level performed at the same time 
returned 0.3mmol/L (therapeutic 0.6-1.2mmol/L). His ICU course was complicated by cardiac 
arrest and respiratory failure requiring intubation. Throughout his hospital stay, his mother 
denied that he could have overdosed on medication because she administered them to him and 
all tablets were accounted for based on pharmacy fill date and time since last refill. On hospital 
day 3, he had recovered enough to be extubated, but was still too delirious to provide additional 
history. On hospital day 4, he had several bowel movements containing apparent tablets, 
ultimately totaling 47 units. He eventually became lucid enough to reveal that he had kept an 
old prescription of bupropion XL and confirmed that this was the medication he had taken. He 
recovered fully with aggressive supportive care and was discharged to inpatient psychiatry.  
The presence of “ghost tablets” in feces, from which the active drug has been absorbed, has 
been previously reported with certain XR dosage forms used at therapeutic doses, but not in a 
case of overdose. Common medications that are known to cause this phenomenon include 
potassium chloride, pseudoephedrine, fexofenadine/pseudoephedrine, metoprolol succinate, 
and oxycodone.2,3 These formulations consist either of insoluble housing compartments for 
osmotic-release drug delivery or of inert matrices coated or filled with drug that rely on 
diffusion for delivery.1 Once the drug is absorbed, the empty matrices or housing compartments 
continue through the gastrointestinal tract and are excreted in feces. In one study, energy-
dispersive X-ray spectroscopy was done on a potassium chloride tablet prior to administration, 
then following ingestion and recovery from the patient’s feces. Concentrations of potassium 
were high and then undetectable, respectively.3  
Abdominal X-ray did not show tablet burden in our patient; however, based on the composition 
of bupropion XL tablets, no radio-opaque bodies would be expected. Analysis of the recovered 
tablets for residual drug was not performed; however, as this case illustrates, the presence of 
tablets in feces should not be interpreted as a sign that the patient was not exhibiting toxicity 
from bupropion, but rather that the drug was absorbed and the tablet remnants were passed. 
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Healthcare providers should be aware that this phenomenon could occur in cases of known or 
suspected overdose with an XR formulation based on this experience and the medical literature 
documenting it in therapeutic dosing.2  
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Figure 1: 
Stool specimen containing numerous ghost tablets of extended-release bupropion. 
 
Figure 2: 
Close-up of a split bupropion tablet. 
